296 related articles for article (PubMed ID: 3668249)
1. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives.
Cruickshank JM; Pennert K; Sörman AE; Thorp JM; Zacharias FM; Zacharias FJ
J Hypertens; 1987 Aug; 5(4):489-98. PubMed ID: 3668249
[TBL] [Abstract][Full Text] [Related]
2. Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).
Cruickshank JM
Drugs Exp Clin Res; 1990; 16(3):133-6. PubMed ID: 2387213
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and tolerability of antihypertensive treatment based on atenolol in the prevention of stroke and the regression of left ventricular hypertrophy.
Cruickshank JM; Higgins TJ; Pennert K; Thorp JM; Zacharias FM; Zacharias FJ
J Hum Hypertens; 1987 Sep; 1(2):87-93. PubMed ID: 3506623
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
5. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
[TBL] [Abstract][Full Text] [Related]
6. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Hansson L
J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
[TBL] [Abstract][Full Text] [Related]
7. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
10. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
[TBL] [Abstract][Full Text] [Related]
11. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
12. Postprandial hypotension predicts all-cause mortality in older, low-level care residents.
Fisher AA; Davis MW; Srikusalanukul W; Budge MM
J Am Geriatr Soc; 2005 Aug; 53(8):1313-20. PubMed ID: 16078956
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study.
Mallion JM; Genès N; Vaur L; Clerson P; Vaïsse B; Bobrie G; Chatellier G
J Hum Hypertens; 2001 Dec; 15(12):841-8. PubMed ID: 11773986
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
16. Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions.
Black HR
J Hypertens Suppl; 1999 Dec; 17(5):S49-54. PubMed ID: 10706327
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
[TBL] [Abstract][Full Text] [Related]
18. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
[TBL] [Abstract][Full Text] [Related]
19. Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
Shimamoto K; Fujita T; Ito S; Naritomi H; Ogihara T; Shimada K; Tanaka H; Yoshiike N;
Hypertens Res; 2008 Mar; 31(3):469-78. PubMed ID: 18497466
[TBL] [Abstract][Full Text] [Related]
20. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
